HungaryHungary

Solvo Ranked 4th in Fast 50 Award

23.11.2003

Budapest - Solvo Biotechnology was awarded 4th place among the so called 'Rising Stars' in Deloitte & Touche's Technology Fast 50, an annual award honouring the fastest growing Central European technology companies. The 'Rising Stars' include those in business for less than five years. Eight countries participated in 2003 - the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia. “This is an important recognition for us”, says Erno Duda, CEO of Solvo. “It shows that a healthy biotechnology sector is developing in Hungary.” The company is active in the field of ABC-transporters and drug resistance and holds patents related to drug targets and modulators, gene therapy applications and diagnostics.

HungaryHungary

19.03.2008

Zagreb – Pliva d.d., Barr Pharmaceuticals‘ subsidiary in Croatia, is selling its three operations in Spain – Pliva Pharma Iberia, Laboratorios Edigen and Uso Racional – to Biomedica Foscama Industria Chimico-Farmaceutica. For a...

HungaryHungary

19.03.2008

Budapest – A Hungarian research consortium has been granted a 3-year fund of EUR2m by the Hungarian government to identify new enzyme targets against multi-restistant strains of the tuberculosis agent Mycobacterium tuberculosis...

HungaryHungary

19.02.2008

Debrecen – Israeli generic drugmaker Teva Pharmaceutical Industries is looking to expand its presence in Hungary. The pharma company wants to double capacity at its plant in Debrecen. This will involve a EUR70 million investment...

HungaryHungary

01.01.2008

Szeged – The development of inhibitors directed against matrix metalloproteinases is at the centre of a new funding project sponsored by the Hungarian National Office for Research and Technology (NKTH). The NKTH recently granted...

HungaryHungary

22.11.2007

Budapest/Mumbai – Solvo Biotechnology (Budapest) and Krishgen BioSystems (Mumbai, India) have formed a partnership to distribute and represent Solvo’s membrane transporter assay products and services in India. “Membrane...

HungaryHungary

24.09.2007

Sofia – Icelandic Actavis Group announced double-digit growth in Bulgaria in the first half of 2007. Sales were up 10,65% with more than €23.1 million and 24 new products launched in the first six months of 2007. “Actavis...

HungaryHungary

11.07.2007

Budapest – A new National Alliance for Rare Diseases in Hungary, termed Huferdis – Rare Diseases Hungary (Hungarian Federation of People with Rare and Congenital Diseases), was announced at the beginning of June. “The importance...

HungaryHungary

16.03.2007

Budapest – The EU Environment Council, made up of the European Ministers for the Environment, rejected the proposal in February from the European Commission to lift the Hungarian prohibition to grow genetically modified maize...

HungaryHungary

21.11.2006

Gödöllö – At the end of September, GlaxoSmithKline (GSK) inaugurated a new a100-million vaccine production plant 30 km northeast of the Hungarian capital.According to GSK, the new facility will be one of Europe’s most advanced...

HungaryHungary

21.07.2006

Sofia – On June 1 a law banning the production and sale of a range of genetically modified organisms (GMOs), including wheat, came into effect in Bulgaria. The law represents an about-face for the country, which has experimented...

Displaying results 21 to 30 out of 89

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-hungary/browse/2/article/solvo-ranked-4th-in-fast-50-award.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events